Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Colorectal Cancer Pulmonary Metastasectomy: When, Why and How

Francesco Petrella
* ORCID logo ,
Federica Danuzzo
ORCID logo ,
Maria Chiara Sibilia
,
Sara Vaquer
,
Raffaella Longarini
,
Alessandro Guidi
,
Federico Raveglia
,
Lidia Libretti
,
Emanuele Pirondini
,
Andrea Cara
,
Enrico Mario Cassina
,
Antonio Tuoro
,
Diego Cortinovis
Version 1 : Received: 14 March 2024 / Approved: 15 March 2024 / Online: 15 March 2024 (15:04:29 CET)

A peer-reviewed article of this Preprint also exists.

Petrella, F.; Danuzzo, F.; Sibilia, M.; Vaquer, S.; Longarini, R.; Guidi, A.; Raveglia, F.; Libretti, L.; Pirondini, E.; Cara, A.; et al. Colorectal Cancer Pulmonary Metastasectomy: When, Why and How. Cancers 2024, 16, 1408, doi:10.3390/cancers16071408. Petrella, F.; Danuzzo, F.; Sibilia, M.; Vaquer, S.; Longarini, R.; Guidi, A.; Raveglia, F.; Libretti, L.; Pirondini, E.; Cara, A.; et al. Colorectal Cancer Pulmonary Metastasectomy: When, Why and How. Cancers 2024, 16, 1408, doi:10.3390/cancers16071408.

Abstract

Colorectal cancer is the third most diagnosed cancer in males and in females, representing 8% of estimated new cases and the third cause of cancer-related death in both sexes, accounting for 9% of cancer deaths in men and 8% in women. About 20% of patients diagnosed with CRC present metastatic disease. Although lung metachronous or synchronous metastatic spread without other involved sites has been reported in only a small proportion of patients, considering that this tumor is frequently diagnosed, the clinical approach to CRC pulmonary metastases represents a major issue for thoracic surgeons and CRC oncologists. Among patients diagnosed with pulmonary metastases from CRC, about 9 – 12% are eligible for local treatments with radical intent, including surgical resection, SBRT and ablation therapy. Due to the lack of randomized controlled trials among different local strategies, there is no definitive evidence about the optimal approach, although surgical resection is considered the most effective therapeutic option in this clinical scenario. Oncological achievement of primary radical resection, the biology of primary tumor and metastatic sites, disease free interval and or progression free survival are independent prognostic factors which make it possible to define a cohort of patients which might significantly benefit from pulmonary metastasectomy.

Keywords

colorectal cancer; pulmonary metastasectomy; disease free interval; overall survival.

Subject

Medicine and Pharmacology, Surgery

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.